Update in Nephrology and Hypertension
Authors: Paul L. Kimmel
Journal: Annals of Internal Medicine (2006)

Updates21 February 2006Update in Nephrology and HypertensionPaul L. Kimmel, MDPaul L. Kimmel, MDFrom George Washington University Medical Center, Washington, DC.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-144-4-200602210-00010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This Update in Nephrology and Hypertension addresses common clinical problems facing general internists and nephrologists. I have included papers that presented a new way of classifying chronic kidney disease and expanded our knowledge of the risks associated with this diagnosis, established a new association between chronic kidney disease and the metabolic syndrome, and compared the equations that are used to define chronic kidney disease. I have also included noteworthy research regarding the prevention and treatment of diabetic nephropathy; hyperkalemia; and the prevention of contrast agent–induced nephropathy, which is a concern for many internists and nephrologists.Chronic Kidney DiseaseProteinuria and ...References1. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-6. [PMID: 11466120] CrossrefMedlineGoogle Scholar2. Best PJ, Reddan DN, Berger PB, Szczech LA, McCullough PA, Califf RM. Cardiovascular disease and chronic kidney disease: insights and an update. Am Heart J. 2004;148:230-42. [PMID: 15308992] CrossrefMedlineGoogle Scholar3. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis. 2004;44:198-206. [PMID: 15264177] CrossrefMedlineGoogle Scholar4. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-95. [PMID: 15385655] CrossrefMedlineGoogle Scholar5. Hostetter TH. Chronic kidney disease predicts cardiovascular disease [Editorial]. N Engl J Med. 2004;351:1344-6. [PMID: 15385664] CrossrefMedlineGoogle Scholar6. National Kidney Disease Education Program. Health professionals MDRD calculator for adults. Accessed at nkdep.nih.gov/professionals/gfr_calculators/mdrd.htm on 3 January 2006. Google Scholar7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9. [PMID: 11790215] CrossrefMedlineGoogle Scholar8. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-36. [PMID: 12588201] CrossrefMedlineGoogle Scholar9. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444-9. [PMID: 15451914] CrossrefMedlineGoogle Scholar10. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12. [PMID: 12500213] CrossrefMedlineGoogle Scholar11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-70. [PMID: 10075613] LinkGoogle Scholar12. Cook DJ, Guyatt GH. Interpreting, integrating, and individualizing evidence about the prevention of diabetic nephropathy [Editorial]. Ann Intern Med. 1999;131:707-8. [PMID: 10577335] LinkGoogle Scholar13. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med. 1999;131:660-7. [PMID: 10577328] LinkGoogle Scholar14. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med. 2001;134:370-9. [PMID: 11242497] LinkGoogle Scholar15. Mitch WE. Treating diabetic nephropathy—are there only economic issues? N Engl J Med. 2004;351:1934-6. [PMID: 15516698] CrossrefMedlineGoogle Scholar16. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-61. [PMID: 15516696] CrossrefMedlineGoogle Scholar17. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17. [PMID: 10471456] CrossrefMedlineGoogle Scholar18. Jarman PR, Mather HM. Diabetes may be independent risk factor for hyperkalaemia [Letter]. BMJ. 2003;327:812. [PMID: 14525902] CrossrefMedlineGoogle Scholar19. Ghali WA, Cornuz J. Early uptake of research findings after fast-track publication [Letter]. Lancet. 2000;355:579-80. [PMID: 10683036] CrossrefMedlineGoogle Scholar20. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-4. [PMID: 12535810] CrossrefMedlineGoogle Scholar21. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21. [PMID: 12668699] CrossrefMedlineGoogle Scholar22. Briguori C, Tavano D, Colombo A. Contrast agent—associated nephrotoxicity. Prog Cardiovasc Dis. 2003;45:493-503. [PMID: 12800130] CrossrefMedlineGoogle Scholar23. Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med. 2004;2:38. [PMID: 15500690] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From George Washington University Medical Center, Washington, DC.Disclosures: None disclosed.Corresponding Author: Paul L. Kimmel, MD, Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue NW, Washington, DC 20037; e-mail, [email protected]gwu.edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByLong-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trialInappropriate ICD discharges due to “triple counting” during normal sinus rhythm 21 February 2006Volume 144, Issue 4Page: 281-285KeywordsACE inhibitorsBicarbonatesChronic kidney diseaseCreatinineHospitalizationsMetabolic syndromeMicroalbuminuriaRenal diseasesSodiumSodium chloride ePublished: 21 February 2006 Issue Published: 21 February 2006 CopyrightCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...